Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout

NCT05007392 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT05007392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05007392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 21, 2021
Completion date
June 14, 2023
Enrollment
451 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

gout